Phase 2 Macular Degeneration Trial, Recruiting (NCT06087458)

Phase 2 Macular Degeneration Trial, Recruiting NCT06087458 Sponsor: Perceive Biotherapeutics, Inc. Condition: Macular Degeneration

Printed from Voxsanity (voxsanity.com.au) — NCT06087458 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Macular Degeneration

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who are 60 years of age or older at the time of signing the consent form
People who are willing and able to understand the study and sign a written consent form
People who are able to attend scheduled treatment visits and follow-up appointments
People who are able to complete standardised vision testing and eye imaging
People who have clearly defined geographic atrophy (a type of damage to the central part of the eye) caused by age-related macular degeneration (AMD), with no current or past history of abnormal blood vessel growth in either eye
People who show no signs of a specific type of hidden abnormal blood vessel growth in the eye (confirm with trial site)
People whose eyes meet additional specific eye-related criteria set by the trial (confirm with trial site)
People whose genetic profile meets certain criteria related to AMD risk (confirm with trial site)

Who may not be able to join:

Women who are able to become pregnant and are currently pregnant, or who are unwilling to use and keep records of effective contraception for the full duration of the study
People who do not meet additional health, eye, or genetic criteria set by the trial (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 22 July 2026

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Anne Fung, MD, Perceive Biotherapeutics, Inc.

Phone: (800) 867-7960

Australian sites

Sydney Retina Clinic and Day Surgery, Sydney, New South Wales

Cerulea Clinical Trials, East Melbourne, Victoria

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06087458

Sponsor: Perceive Biotherapeutics, Inc.

Phase: Phase 2

Status: Recruiting

Condition: Macular Degeneration

Trial contact: (800) 867-7960

More information: https://clinicaltrials.gov/study/NCT06087458

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who are 60 years of age or older at the time of signing the consent form
People who are willing and able to understand the study and sign a written consent form
People who are able to attend scheduled treatment visits and follow-up appointments
People who are able to complete standardised vision testing and eye imaging
People who have clearly defined geographic atrophy (a type of damage to the central part of the eye) caused by age-related macular degeneration (AMD), with no current or past history of abnormal blood vessel growth in either eye
People who show no signs of a specific type of hidden abnormal blood vessel growth in the eye (confirm with trial site)
People whose eyes meet additional specific eye-related criteria set by the trial (confirm with trial site)
People whose genetic profile meets certain criteria related to AMD risk (confirm with trial site)

Who may not be able to join:

Women who are able to become pregnant and are currently pregnant, or who are unwilling to use and keep records of effective contraception for the full duration of the study
People who do not meet additional health, eye, or genetic criteria set by the trial (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 22 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 2

Sponsor

Perceive Biotherapeutics, Inc.

Registry

ClinicalTrials.gov

Start date

21 June 2023

Est. completion

1 June 2027

Where this trial is recruiting

🇦🇺 Australia 🇮🇱 Israel 🇺🇸 United States

2 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Overall effect of treatment on retinal structural health

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov